Vahid Bagheri1, Hossein Khorramdelazad1, Gholamhossein Hassanshahi1, Amir Moghadam-Ahmadi2,3, Alireza Vakilian4,5. 1. Molecular Medicine Research Center, Research Institute of Basic Medical Sciences, Rafsanjan University of Medical Sciences, Rafsanjan, Iran. 2. Non-Communicable Diseases Research Center, Rafsanjan University of Medical Sciences, Rafsanjan, Iran. 3. Geriatric Care Research Center, Rafsanjan University of Medical Sciences, Rafsanjan, Iran. 4. Geriatric Care Research Center, Rafsanjan University of Medical Sciences, Rafsanjan, Iran, alirezavakilian7@gmail.com. 5. Department of Neurology, Ali-ebn-Abitaleb Hospital, Rafsanjan University of Medical Sciences, Rafsanjan, Iran, alirezavakilian7@gmail.com.
Abstract
OBJECTIVE: The role of CXCL12 and its receptor CXCR4 has not been fully examined in Parkinson's disease (PD). The purpose of this study was to investigate the role of CXCL12/CXCR4 in the peripheral blood of patients with PD and healthy controls. METHODS: CXCL12 serum levels and CXCR4 mRNA levels were measured in 30 PD patients and 40 controls using ELISA and real-time PCR, respectively. RESULTS: CXCL12 serum levels were significantly higher in PD patients compared to controls (p < 0.0001). Moreover, CXCR4 expression in peripheral blood mononuclear cells (PBMC) of PD patients was significantly increased compared to controls (p < 0.0001). CONCLUSIONS: Our findings provide new information on the expression of CXCL12/CXCR4 in PD. CXCR4 expression in PBMC or CXCL12 serum levels may be potential biomarkers of inflammation in PD patients.
OBJECTIVE: The role of CXCL12 and its receptor CXCR4 has not been fully examined in Parkinson's disease (PD). The purpose of this study was to investigate the role of CXCL12/CXCR4 in the peripheral blood of patients with PD and healthy controls. METHODS:CXCL12 serum levels and CXCR4 mRNA levels were measured in 30 PDpatients and 40 controls using ELISA and real-time PCR, respectively. RESULTS:CXCL12 serum levels were significantly higher in PDpatients compared to controls (p < 0.0001). Moreover, CXCR4 expression in peripheral blood mononuclear cells (PBMC) of PDpatients was significantly increased compared to controls (p < 0.0001). CONCLUSIONS: Our findings provide new information on the expression of CXCL12/CXCR4 in PD. CXCR4 expression in PBMC or CXCL12 serum levels may be potential biomarkers of inflammation in PDpatients.
Authors: Hung Li Wang; Chin Song Lu; Tu Hsueh Yeh; Yu Ming Shen; Yi Hsin Weng; Ying Zu Huang; Rou Shayn Chen; Yu Chuan Liu; Yi Chuan Cheng; Hsiu Chen Chang; Ying Ling Chen; Yu Jie Chen; Yan Wei Lin; Chia Chen Hsu; Huang Li Lin; Chi Han Chiu; Ching Chi Chiu Journal: J Clin Neurol Date: 2019-10 Impact factor: 3.077